Session » RA – Treatments Poster III: Safety and Outcomes

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2353

ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices

9:00AM-11:00AM: Abstract Number: 2403

Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings

9:00AM-11:00AM: Abstract Number: 2355

Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2356

Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2362

Associations of Disease-Modifying Anti-Rheumatic Drug (DMARD) Adherence with Time to First Biologic and Cycle Time on DMARDs, and Healthcare Utilization/Cost in a New RA Patient Cohort

9:00AM-11:00AM: Abstract Number: 2381

Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA

9:00AM-11:00AM: Abstract Number: 2399

Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis

9:00AM-11:00AM: Abstract Number: 2378

Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA

9:00AM-11:00AM: Abstract Number: 2366

Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 2386

Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2370

Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2395

DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment

9:00AM-11:00AM: Abstract Number: 2396

DNA Methylation of the Dual Specificity Phosphatase 22 (DUSP22) Gene Promoter in Plasma and Medication Use in Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 2404

Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 2361

Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico

9:00AM-11:00AM: Abstract Number: 2391

Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2385

Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study

9:00AM-11:00AM: Abstract Number: 2401

Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate

9:00AM-11:00AM: Abstract Number: 2406

Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry

9:00AM-11:00AM: Abstract Number: 2359

High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2379

High Initial Methotrexate Dose Is Not Associated with an Increased Risk of Liver Toxicity in Korean Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2380

Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome

9:00AM-11:00AM: Abstract Number: 2363

Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy

9:00AM-11:00AM: Abstract Number: 2387

Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice

9:00AM-11:00AM: Abstract Number: 2377

Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 2357

Methotrexate Liver Toxicity in a Large Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2376

Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2374

MRI of the Wrist in Early Rheumatoid Arthritis After 1-year Treat-to-target Strategy

9:00AM-11:00AM: Abstract Number: 2364

Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development

9:00AM-11:00AM: Abstract Number: 2388

Patient Characteristics Associated with Long Term Glucocorticoid Use in a Commercially Insured Incident RA Cohort

9:00AM-11:00AM: Abstract Number: 2372

Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 2390

Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission

9:00AM-11:00AM: Abstract Number: 2398

Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions

9:00AM-11:00AM: Abstract Number: 2405

Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2352

Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2382

Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2354

Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2365

Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus

9:00AM-11:00AM: Abstract Number: 2368

Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study

9:00AM-11:00AM: Abstract Number: 2371

Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database

9:00AM-11:00AM: Abstract Number: 2393

Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials

9:00AM-11:00AM: Abstract Number: 2375

Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports

9:00AM-11:00AM: Abstract Number: 2360

Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2358

Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials

9:00AM-11:00AM: Abstract Number: 2397

Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer

9:00AM-11:00AM: Abstract Number: 2400

The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results Form a Nationwide Registry

9:00AM-11:00AM: Abstract Number: 2367

The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2392

The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2407

The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2389

Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed

9:00AM-11:00AM: Abstract Number: 2383

Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed

9:00AM-11:00AM: Abstract Number: 2369

Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2373

Two Decades of Changes in RA Treatment and Disease Outcomes from the United States

9:00AM-11:00AM: Abstract Number: 2394

Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit

9:00AM-11:00AM: Abstract Number: 2402

Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 2351

Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis

9:00AM-11:00AM: Abstract Number: 2384

Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].